Online inquiry

IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1378MR)

This product GTTS-WQ1378MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL12B gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002187.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3593
UniProt ID P29460
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ1378MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13866MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ6828MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ13548MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRX-302
GTTS-WQ13441MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ5513MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ689MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ15846MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ8946MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW